Is there an authoritarian advantage in pandemic response? a comparative case study of China's responses to SARS-CoV-1 (2003) and SARS-CoV-2 (2019)/ Jonathan Schwartz

Effective pandemic response has become an increasingly important focus for research in the face of the COVID-19 pandemic. While there are a number of variables that may be considered as influencing effective response, this paper focuses on the potential impact of an "authoritarian advantage" in achieving an effective response in the period prior to pharmaceutical interventions being available with China as a case study. In essence, this paper explores whether China enjoys an authoritarian advantage, and if so, how it functions. This study compares China's SARS-CoV-1 (2003) response with its SARS-CoV-2 (2019) response by exploring the impact of the authoritarian advantage on the state's ability to effectively engage three key explanatory variables - centralized decision-making powers, public support and media engagement. SARS-CoV-2 is the virus known as severe acute respiratory syndrome coronavirus 2. The disease SARS-CoV-2 causes is COVID-19 (coronavirus disease 2019). SARS-CoV-1 is the virus known as severe acute respiratory syndrome coronavirus 1. It causes SARS (2003).

CHINA, COVID-19, HEALTH